Psilocybin Shows Promise in Preventing Relapse in Alcohol Use Disorder with Depression
Preliminary results indicate that psilocybin-assisted psychotherapy significantly reduces drinking days and craving frequency in individuals with AUD and depressive symptoms.
Phase III
Addiction / Psilocybin
Status
Positive
Signal Score
8.4
Signal assessment
Signal strength
high
Confidence level
high
Strategic implication
Pharma companies should monitor the outcomes of this trial as it may influence future treatment strategies and investment in psychedelic therapies for addiction.
Why it matters
The promising results of psilocybin-assisted psychotherapy in reducing relapse rates for individuals with Alcohol Use Disorder and depression could reshape treatment paradigms in addiction therapy. This trial highlights a significant opportunity for pharma companies to explore and invest in psychedelic therapies, which are currently underrepresented in the market.
Recommended action
Humanexa recommends Monitor.
Analysis
Follow the results of the ERPPAD trial comparing high-dose and low-dose psilocybin-assisted psychotherapy over the next 6 months.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.